Ogier advises Bull Horn Holdings SPAC on US$175 million merger with Coeptis Therapeutics

Ogier has acted as British Virgin Islands counsel to Nasdaq-listed SPAC Bull Horn Holdings Corp in its merger with Coeptis Therapeutics, a biopharmaceutical company that develops innovative cell therapy technologies for cancer.

The deal, valued at around US$175 million, was originally signed in April 2022 and closed on 27 October 2022 following the approval of Bull Horn's shareholders, who now hold approximately 12% of the equity of the combined company, with the balance being held by Coeptis' former stockholders.

For this transaction, the Ogier team was led by partner Michael Killourhy and included managing associate David Mathews.

Speaking about the transaction, Michael said, "We have advised Bull Horn since their US$75 million IPO in November 2020 and it was a pleasure to work with them on their business combination. Ogier has successfully completed a number of these transactions recently and our BVI SPAC practice continues to go from strength to strength."

Bull Horn was advised in the US by Ellenoff Grossman & Schole LLP, with Meister Seelig & Fein LLP advising Coeptis.